Early Taurine Administration Decreases the Levels of Receptor-Interacting Serine/Threonine Protein Kinase 1 in the...

Background/Objectives: The progressive life-limiting disorder Duchenne muscular dystrophy (DMD) arises from the absence of dystrophin protein at the muscle cell membrane, which leads to progressive contraction-induced damage. Despite the advancements in molecular therapies aimed at reintroducing (partially functional) dystrophin in patients, a cure for DMD remains elusive. Taurine supplements have been proposed as a potential supportive treatment for DMD, based upon encouraging results in the mouse model mdx. Methods: In a previous study, we observed improvements in skeletal muscle histology and a reduction in the expression of inflammatory markers after short-term treatment with 4.6 g taurine per kg body weight during the initial stages of the disease. In this follow-up study, we examined cell death and tissue restoration protein levels in mdx subjected to the same treatment regimen, utilizing proteome arrays, Western blotting, and immunofluorescence. Results: We report that, while the levels of apoptotic and autophagic proteins remained constant, selective and significant decrease in receptor-interacting Serine/Threonine protein kinase 1 (RIP1) levels could be observed in taurine-treated mdx compared to untreated mdx. RIP1 was immunolocalized to muscle fibers, with faint homogeneous staining in age-matched healthy controls shifting to a heterogeneous staining pattern in mdx, the latter diminishing with taurine treatment. Conclusions: Given its role as a molecular switch in cell fate decisions, the observed taurine-induced downregulation of RIP1 supports the potential beneficial effects of the osmolyte in mdx.